Celeste A. Johns

3.3k total citations
34 papers, 2.5k citations indexed

About

Celeste A. Johns is a scholar working on Psychiatry and Mental health, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Celeste A. Johns has authored 34 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Psychiatry and Mental health, 7 papers in Pharmacology and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in Celeste A. Johns's work include Schizophrenia research and treatment (18 papers), Bipolar Disorder and Treatment (9 papers) and Tryptophan and brain disorders (6 papers). Celeste A. Johns is often cited by papers focused on Schizophrenia research and treatment (18 papers), Bipolar Disorder and Treatment (9 papers) and Tryptophan and brain disorders (6 papers). Celeste A. Johns collaborates with scholars based in United States, Austria and Germany. Celeste A. Johns's co-authors include John M. Kane, Jeffrey A. Lieberman, Thomas Horvath, Richard C. Mohs, Blaine Greenwald, Simcha Pollack, Aleksander A. Mathé, J.A. Lieberman, Kenneth L. Davis and Keith L. Davis and has published in prestigious journals such as Science, American Journal of Psychiatry and Biological Psychiatry.

In The Last Decade

Celeste A. Johns

34 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Celeste A. Johns United States 21 1.5k 433 391 387 362 34 2.5k
Sukdeb Mukherjee United States 27 1.8k 1.2× 305 0.7× 289 0.7× 416 1.1× 645 1.8× 84 3.1k
H.Y. Meltzer United States 27 1.9k 1.3× 1.1k 2.6× 420 1.1× 303 0.8× 368 1.0× 67 3.4k
David L. Garver United States 28 988 0.7× 591 1.4× 259 0.7× 322 0.8× 355 1.0× 82 2.3k
Gohei Yagi Japan 26 1.2k 0.8× 458 1.1× 245 0.6× 142 0.4× 527 1.5× 93 2.4k
Eduard Parellada Spain 30 1.4k 0.9× 384 0.9× 180 0.5× 478 1.2× 342 0.9× 98 2.5k
Herbert Y. Meltzer United States 19 1.1k 0.7× 905 2.1× 482 1.2× 335 0.9× 293 0.8× 22 2.2k
Kenneth Alper United States 31 1.6k 1.0× 977 2.3× 192 0.5× 807 2.1× 291 0.8× 65 3.5k
Thomas J. Raedler Germany 21 946 0.6× 667 1.5× 223 0.6× 543 1.4× 257 0.7× 46 2.5k
H.‐J. Möller Germany 27 1.0k 0.7× 228 0.5× 413 1.1× 671 1.7× 273 0.8× 55 2.6k
Burt Angrist United States 23 1.2k 0.8× 765 1.8× 235 0.6× 464 1.2× 210 0.6× 61 2.2k

Countries citing papers authored by Celeste A. Johns

Since Specialization
Citations

This map shows the geographic impact of Celeste A. Johns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Celeste A. Johns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Celeste A. Johns more than expected).

Fields of papers citing papers by Celeste A. Johns

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Celeste A. Johns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Celeste A. Johns. The network helps show where Celeste A. Johns may publish in the future.

Co-authorship network of co-authors of Celeste A. Johns

This figure shows the co-authorship network connecting the top 25 collaborators of Celeste A. Johns. A scholar is included among the top collaborators of Celeste A. Johns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Celeste A. Johns. Celeste A. Johns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Scribani, Melissa, et al.. (2018). The 9-Item Patient Health Questionnaire (PHQ-9): an aid to assessment of patient-reported functional outcomes after spinal surgery. The Spine Journal. 18(8). 1398–1405. 27 indexed citations
2.
Sensky, Tom, et al.. (1998). A randomized controlled trial of cognitive behaviour therapy in the management of treatment-resistant schizophrenia. Schizophrenia Research. 29(1-2). 164–164. 4 indexed citations
3.
Garey, Kevin W., Guy W. Amsden, & Celeste A. Johns. (1997). Possible Interaction Between Imipramine and Butalbital. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(5). 1041–1042. 3 indexed citations
4.
Johns, Celeste A. & Jill Thompson. (1995). Adjunctive Treatments in Schizophrenia: Pharmacotherapies and Electroconvulsive Therapy. Schizophrenia Bulletin. 21(4). 607–619. 43 indexed citations
5.
Kane, John M., Allan Z. Safferman, Simcha Pollack, et al.. (1994). Clozapine, negative symptoms, and extrapyramidal side effects.. PubMed. 55 Suppl B. 74–7. 23 indexed citations
6.
Lieberman, J.A., Allan Z. Safferman, Simcha Pollack, et al.. (1994). Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. American Journal of Psychiatry. 151(12). 1744–1752. 304 indexed citations
7.
Safferman, Allan Z., et al.. (1993). Predictors of response to clozapine in chronic schizophrenia. Schizophrenia Research. 9(2-3). 249–249. 1 indexed citations
8.
Kinon, Bruce J., et al.. (1993). Treatment of neuroleptic-resistant schizophrenic relapse.. PubMed. 29(2). 309–14. 96 indexed citations
9.
Bogerts, Bernhard, Jeffrey A. Lieberman, Manzar Ashtari, et al.. (1993). Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia. Biological Psychiatry. 33(4). 236–246. 272 indexed citations
10.
Bogerts, B., J.A. Lieberman, Robert M. Bilder, et al.. (1992). A VOLUMETRIC MRI STUDY OF LIMBIC STRUCTURES IN CHRONIC SCHIZOPHRENIA - RELATIONSHIP TO PSYCHOPATHOLOGY. Clinical Neuropharmacology. 15. 112A–113A. 4 indexed citations
11.
Lemus, Carmen Z., Jeffrey A. Lieberman, Celeste A. Johns, et al.. (1991). Hormonal response to fenfluramine challenges in clozapine-treated schizophrenic patients. Biological Psychiatry. 29(7). 691–694. 12 indexed citations
12.
Lieberman, J.A., Bruce L. Saltz, Celeste A. Johns, et al.. (1991). The Effects of Clozapine on Tardive Dyskinesia. The British Journal of Psychiatry. 158(4). 503–510. 220 indexed citations
13.
Lemus, Carmen Z., et al.. (1990). CSF 5-hydroxyindoleacetic acid levels and suicide attempts in schizophrenia. Biological Psychiatry. 27(8). 926–929. 17 indexed citations
14.
Lemus, Carmen Z., Jeffrey A. Lieberman, & Celeste A. Johns. (1989). Myoclonus during treatment with clozapine and lithium: the role of serotonin.. PubMed. 11(2). 127–30. 14 indexed citations
15.
Kanof, Philip D., Emil F. Coccaro, Celeste A. Johns, et al.. (1989). Cyclic-AMP production by polymorphonuclear leukocytes in psychiatric disorders. Biological Psychiatry. 25(4). 413–420. 11 indexed citations
16.
Lieberman, Jeffrey A., Celeste A. Johns, Thomas B. Cooper, Simcha Pollack, & John M. Kane. (1989). Clozapine pharmacology and tardive dyskinesia. Psychopharmacology. 99(S1). S54–S59. 45 indexed citations
17.
Kanof, Philip D., Celeste A. Johns, Michael Davidson, et al.. (1988). Platelet alpha2-adrenergic receptor function in psychiatric disorders. Psychiatry Research. 23(1). 11–22. 13 indexed citations
18.
Losonczy, Miklos, R C Mohs, Neil Small, et al.. (1986). Correlates of lateral ventricular size in chronic schizophrenia, I: Behavioral and treatment response measures. American Journal of Psychiatry. 143(8). 976–981. 68 indexed citations
19.
Greenwald, Blaine, Aleksander A. Mathé, Richard C. Mohs, et al.. (1986). Cortisol and Alzheimer's disease, II: Dexamethasone suppression, dementia severity, and affective symptoms. American Journal of Psychiatry. 143(4). 442–446. 115 indexed citations
20.
Mohs, Richard C., Belinda Davis, Celeste A. Johns, et al.. (1985). Oral physostigmine treatment of patients with Alzheimer's disease. American Journal of Psychiatry. 142(1). 28–33. 183 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sukdeb Mukherjee Breakdown of academic impact, for papers by H.Y. Meltzer Breakdown of academic impact, for papers by David L. Garver Breakdown of academic impact, for papers by Gohei Yagi Breakdown of academic impact, for papers by Eduard Parellada Breakdown of academic impact, for papers by Herbert Y. Meltzer Breakdown of academic impact, for papers by Kenneth Alper Breakdown of academic impact, for papers by Thomas J. Raedler Breakdown of academic impact, for papers by H.‐J. Möller Breakdown of academic impact, for papers by Burt Angrist
Rankless by CCL
2026